Early life exposure to oestrogen and testicular cancer risk: evidence against an aetiological hypothesis by Hsieh, C C et al.
REFERENCES
Ade ￿laı ¨de J, Penault-Llorca F, Dib A, Yarden Y, Jacquemier J, Birnbaum D
(1994) The Heregulin gene can be included in the 8p12 ampliﬁcation unit
in breast cancer. Genes Chromosomes Cancer 11: 66–69
Ade ￿laı ¨de J, Chaffanet M, Imbert A, Allione F, Geneix J, Popovici C, van
Alewijk D, Trapman R, Zeillinger R, Borresen-Dale AL, Liderau R, Birn-
baum D, Pe ￿busque M-J (1998) Chromosome 8p11-p12 region: reﬁned
mapping and molecular alterations in breast cancer. Genes Chromosomes
Cancer 22: 186–199
Ade ￿laı ¨de J, Chaffanet M, Mozziconacci M-J, Popovici C, Conte N, Ferna ￿ndez
F, Sobol H, Jacquemier J, Pe ￿busque M-J, Ron D, Lafage-Pochitaloff M,
Birnbaum D (2000) Translocation and coampliﬁcation of loci from chro-
mosome arms 8p and 11q in the MDA-MB-175 mammary carcinoma cell
line. Int J Oncol 16: 683–688
Burden S, Yarden Y (1997) Neuregulins and their receptors: a versatile signal-
ling module in organogenesis and oncogenesis. Neuron 18: 847–855
Carraway KL, Carraway CA, Carraway KL (1997) Roles of ErbB3 and ErbB4
in the physiology and pathology of the mammary gland. J Mammary Gland
Biol Neoplasia 2: 187–198
Courtay-Cahen C, Morris JS, Edwards PAW (2000) Chromosome transloca-
tions in breast cancer with breakpoints at 8p12. Genomics 66: 15–25
Holmes WE, Sliwkowski MX, Akita RW, Henzel WJ, Lee J, Park JW, Yansura
D, Abadi N, Raab H, Lewis GD, Shepard HM, Kuang W-J, Wood WI,
Goeddel DV, Vandlen RL (1992) Identiﬁcation of Heregulin, a speciﬁc
activator of p185
erbB2. Science 256: 1205–1210
Le X-F, McWatters A, Wiener J, Wu J-Y, Mills GB, Bast Jr RC (2000) Anti-
HER2 antibody and heregulin suppress growth of HER2-overexpressing
human breast cancer cells through different mechanisms. Clin Cancer
Res 6: 260–270
Lee J, Wood WI (1993) Assignment of heregulin (HGL) to human chromo-
some 8p22-p11 by PCR analysis of somatic cell hybrid DNA. Genomics 16:
790–791
Lewis GD, Figari I, Fendly B, Wong WL, Carter P, Gorman C, Shepard HM
(1993) Differential responses of human tumor cell lines to anti-p185HER2
monoclonal antibodies. Cancer Immunol Immunother 37: 255–263
Liu X, Baker E, Eyre HJ, Sutherland GR, Zhou M (1999) g-Heregulin: a
fusion gene of DOC-4 and neuregulin-1 derived from a chromosome
translocation. Oncogene 18: 7110–7114
Lupu R, Cardillo M, Cho C, Harris L, Hijazi M, Perez C, Resenberg K, Yang
D, Tang C (1996) The signiﬁcance of heregulin in breast cancer tumor
progression and drug resistance. Breast Cancer Res Treat 38: 57–66
Morris J, Carter N, Ferguson-Smith M, Edwards P (1997) Cytogenetic analy-
sis of three breast carcinoma cell lines using reverse chromosome painting.
Genes Chromosomes Cancer 20: 120–139
Peles E, Yarden Y (1993) Neu and its ligands: from an oncogene to neural
factors. Bioessays 15: 815–824
Ram TG, Kokeny KE, Dilts CA, Ethier SP (1995) Mitogenic activity of neu
differentiation factor/heregulin mimics that of epidermal growth factor
and insulin-like growth factor-I in human mammary epithelial cells. J Cell
Physiol 163: 589–596
Schaefer G, Fitzpatrick VD, Sliwkowski MX (1997) g-Heregulin: a novel here-
gulin isoform that is an autocrine growth factor for the human breast
cancer cell line, MDA-MB-175. Oncogene 15: 1385–1394
Sa ￿nchez I, San Miguel JF, Corral J, Martı ￿nC ,P e ￿rez R, Gonza ￿lez M, Can ˜izo
MC, Orfao A, Gonza ￿lez-Sarmiento R (1995) Gene rearrangement in Acute
non-lymphoblastic leukemia. Correlation with morphological and immu-
nophenotypic characteristics of blast cells. Br J Haematol 89: 104–109
Utada Y, Haga S, Kajiwara T, Kasumi F, Sakamoto G, Nakamura Y, Emi M
(2000) Allelic loss at the 8p22 region as a prognostic factor in large and
estrogen receptor negative breast carcinoma. Cancer 88: 1410–1416
Wang X-Z, Jolicoeur EM, Conte N, Chaffanet M, Zhang Y, Mozziconacci
M-J, Feiner H, Birnbaum D, Pe ￿busque M-J, Ron D (1999) g-heregulin is
the product of a chromosomal translocation fusing the DOC4 and HGL/
NRG1 genes in the MDA-MB-175 breast cancer cell line. Oncogene 18:
5718–5721
Weinstein EJ, Grimm S, Leder P (1998) The oncogene heregulin induces
apoptosis in breast epithelial cells and tumors. Oncogene 17: 2107–2113
Yokota T, Yoshimoto M, Kasumi F, Sakamoto G, Nakamura Y, Emi M (1999)
Localization of a tumor suppressor gene associated with the progression of
human breast carcinoma within a 1-cM interval of 8p22-p23.1. Cancer 85:
447–452
Early life exposure to oestrogen and testicular cancer risk:
evidence against an aetiological hypothesis
CC Hsieh*
,1, M Lambe
2, D Trichopoulos
3, A Ekbom
2, O Akre
2, H-O Adami
2
1University of Massachusetts Cancer Center, 373 Plantation Street, Suite 202, Worcester, Massachusetts, MA 01605, USA;
2Department of Medical
Epidemiology, Karolinska Institute, Stockholm, Sweden;
3Department of Epidemiology and Center for Cancer Prevention, Harvard School of Public Health,
Boston, Massachusetts, MA 02115, USA
DOI: 10.1038/sj/bjc/6600246 www.bjcancer.com
ã 2002 Cancer Research UK
Sir
Testicular cancer has a peak incidence among men aged 25 to 34
years, suggesting early life inﬂuences (Akre et al, 1996). The
hypothesis that exposure to endogenous or environmental oestro-
genic compounds affects embryonic testis and increases the risk
of testicular cancer has been put forth (Sharpe and Skakkeback,
1993). This intriguing hypothesis has acquired momentum and,
in fact, was invoked as the main aetiologic mechanism in a recent
major review (Dearnaley et al, 2001). If prenatal exposure to
oestrogens were indeed important, one would expect that popula-
tions with higher levels of pregnancy oestrogens would experience a
higher rate of testicular cancer. We have studied pregnancy
hormone levels, including oestrogen levels, in two populations with
very different rates of testicular cancer (Lipworth et al, 1999).
Adult pregnant women were recruited from maternity clinics of
Beth Israel Hospital in Boston, MA, USA, and from hospitals *Correspondence: CC Hsieh; E-mail: chung.hsieh@umassmed.edu
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Pregnant women were enrolled during their ﬁrst prenatal visit to
the collaborating maternity clinic. Eligibility requirements included
that the pregnant women had to be less than 40 years old, had no
more than one previous stillborn or liveborn child, took no
hormonal medication during the index pregnancy and had no
prior diagnosis of diabetes mellitus or thyroid disease. Three
hundred and four Caucasian women in Boston and 335 Chinese
women in Shanghai were studied. Pregnancy serum concentrations
of oestradiol-17b (E2) and unconjugated oestriol (E3) were
measured in maternal blood at weeks 16 and 27 of gestation.
Details of the study have been published in this journal (Lipworth
et al, 1999). Levels of E2 and E3 were consistently and signiﬁcantly
higher among Chinese women at both sample 1 and sample 2
(Table 1). The age-standardised rate as well as age-speciﬁc inci-
dence rates of testicular cancer during the period of 1988–1992
for white and Chinese males (aged 15–49) were obtained from
the Connecticut and the Shanghai Cancer Registries, respectively
(Parkin et al, 1997). The rates for Chinese males in Shanghai at
all ages were much lower than those for white males in Connecti-
cut, despite evidence of exposure to higher levels of oestrogens in
utero.
While the hypothesis linking high oestrogen exposure with
testicular cancer and other disorders of the male reproductive
system is ingenious, empirical support so far has been limited.
Our data are incompatible with this hypothesis and, although
they do not conclusively refute it, tend to reduce its
plausibility.
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Table 1 Pregnancy serum concentrations of oestradiol (E2), and oestriol (E3) in Chinese women (Shanghai,
China) and Caucasian women (Boston, USA) (upper panel); age standardised and age-speciﬁc rates of testicular
cancer for Chinese and US males during 1988–1992 (lower panel)
Pregnancy oestrogen concentrations (nmol l
71, mean+s.d.), 1994–1995
(Lipworth et al, 1999)
Samples at 16th weeks of
gestation
Samples at 27th weeks of
gestation
E2 E3 E2 E3
Shanghai, China 20.7+9.7 6.3+3.9 48.2+18.3 21.9+9.5
Boston, US 14.0+6.4 3.9+1.7 39.1+16.6 14.0+4.4
Age-speciﬁc incidence rate of testicular cancer (per 100000), 1988–1992
(Parkin et al, 1997)
ASR 15–19 20–24 25–29 30–34 35–39 40–44 45–49
Shanghai, China 0.74 0.24 0.63 0.39 1.71 1.53 1.44 0.56
Connecticut, US, Whites 5.29 3.60 9.68 14.36 14.87 12.28 9.14 5.81
ASR: age standardised rate, adjusting all the age-speciﬁc rates in 5 year category (0–4, 5–9, ..., 80–84, 85+) to standard world
population (Parkin et al, 1997)
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